【Abstract】 Objective To analyze the effects of hemodialysis combined with hemoperfusion on the clinical efficacy, inflammatory factors and calcium and phosphorus metabolism in patients with chronic renal failure. Methods The clinical data of 105 patients with chronic renal failure admitted to our hospital from May 2017 to June 2019 were retrospectively analyzed. According to the inclusion and exclusion criteria, 102 cases were finally selected as the research objects, and they were divided into combined groups (n=53, hemodialysis combined with hemoperfusion therapy) and single groups (n=49, single hemodialysis therapy) according to the treatment methods. The clinical efficacy, renal function before and after treatment ［β2-microglobulin (β2-MG), serum creatinine (sCr), urea nitrogen (BUN)］, and inflammatory factors (interleukin-1, interleukin-6, high sensitivity C reactive protein and tumor necrosis factor alpha), blood calcium, and blood phosphorus levels were recorded and compared in each group were recorded. The incidence of complications in the two groups was compared. Results Before treatment, there was no difference in β2-MG, SCR, BUN between the two groups (P＞0.05). After treatment, the levels of β2-MG, SCR, and BUN in the combined group were significantly lower than those before treatment, while lower than those of the single group (P＜0.05). Before treatment, there was no difference in the concentration of inflammatory indexes between the two groups (P＞0.05). After treatment, IL-6, CRP and TNFα in the combined group were significantly lower than those before treatment, and at the same time lower than those in the single group (P＜0.05). Before treatment, there was no difference in blood calcium and blood phosphorus levels between the two groups (P＞0.05). After treatment, the blood calcium levels and blood phosphorus levels of the two groups increased, and the blood calcium and blood phosphorus levels of the combined group changed more than the single group(P＜0.05). The incidence of complications in the combined group was 3-77%, the incidence of complications in the single group was 18-37%, and the incidence of complications in the combined group was lower than that of the single group (P＜0.05). Conclusion Hemodialysis combined with hemoperfusion can improve the micro inflammatory state in patients with chronic renal failure, promote the recovery of renal function, and maintain the balance of calcium and phosphorus metabolism in the body. It has good clinical efficacy and low incidence of adverse reactions. It is worthy of clinical promotion.